PURPOSE: Bevacizumab-based chemotherapy has become the standard of care in metastatic colorectal cancer (MCRC). We aimed to measure the levels of serum soluble FAS, FASL, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and its death receptors DR4 and DR5 in MCRC patients and to define prognostic significance of these parameters in response to bevacizumab in these patients. PATIENTS AND METHODS: The levels of these parameters in serum samples were quantified by a commercially available ELISA kit in 31 MCRC patients before and after 2 cycles of therapy and 25 healthy controls. RESULTS: Pretreatment sFAS levels in MCRC patients was significantly lower than the levels of controls (p = 0.043). There was no significant difference in sFAS and sFASL levels in MCRC patients before and after bevacizumab-based treatment. There was no significant difference in sFAS/sFASL ratio in MCRC patients before and after treatment and controls. Soluble DR5 levels were significantly higher in pretreatment serum samples compared with controls (p = 0.008). However, pretreatment sTRAIL and sDR4 levels were similar to the levels of controls. There was no significant difference in sTRAIL, sDR4, and sDR5 levels in MCRC patients before and after treatment. When patients were grouped according to treatment response (responders vs. non-responders), post-treatment sFAS/sFASL ratio was significantly lower in responding patients compared with non-responders (p = 0.029). Significant correlations were observed between post-treatment sFASL and sDR4, sFAS and sTRAIL, sTRAIL and sFAS/sFASL ratio, and sFASL and sDR5. CONCLUSION: Non-significant changes in apoptotic markers with bevacizumab-based chemotherapy showed that they have no prognostic significance in MCRC patients. Significant change in sFAS/sFASL ratio according to treatment response could be an indicator of chemosensitivity.
PURPOSE:Bevacizumab-based chemotherapy has become the standard of care in metastatic colorectal cancer (MCRC). We aimed to measure the levels of serum soluble FAS, FASL, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and its death receptors DR4 and DR5 in MCRC patients and to define prognostic significance of these parameters in response to bevacizumab in these patients. PATIENTS AND METHODS: The levels of these parameters in serum samples were quantified by a commercially available ELISA kit in 31 MCRC patients before and after 2 cycles of therapy and 25 healthy controls. RESULTS: Pretreatment sFAS levels in MCRC patients was significantly lower than the levels of controls (p = 0.043). There was no significant difference in sFAS and sFASL levels in MCRC patients before and after bevacizumab-based treatment. There was no significant difference in sFAS/sFASL ratio in MCRC patients before and after treatment and controls. Soluble DR5 levels were significantly higher in pretreatment serum samples compared with controls (p = 0.008). However, pretreatment sTRAIL and sDR4 levels were similar to the levels of controls. There was no significant difference in sTRAIL, sDR4, and sDR5 levels in MCRC patients before and after treatment. When patients were grouped according to treatment response (responders vs. non-responders), post-treatment sFAS/sFASL ratio was significantly lower in responding patients compared with non-responders (p = 0.029). Significant correlations were observed between post-treatment sFASL and sDR4, sFAS and sTRAIL, sTRAIL and sFAS/sFASL ratio, and sFASL and sDR5. CONCLUSION: Non-significant changes in apoptotic markers with bevacizumab-based chemotherapy showed that they have no prognostic significance in MCRC patients. Significant change in sFAS/sFASL ratio according to treatment response could be an indicator of chemosensitivity.
Authors: Jörn Sträter; Ulf Hinz; Henning Walczak; Gunhild Mechtersheimer; Karin Koretz; Christian Herfarth; Peter Möller; Thomas Lehnert Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: Cristina Nadal; Joan Maurel; Rosa Gallego; Antoni Castells; Raquel Longarón; Maribel Marmol; Sergi Sanz; Rafael Molina; Marta Martin-Richard; Pere Gascón Journal: Clin Cancer Res Date: 2005-07-01 Impact factor: 12.531
Authors: N E Kushlinskii; T A Britvin; S G Abbasova; A G Perevoshchikov; V V Prorokov; I A Kostanyan; V I Knysh; V M Lipkin Journal: Bull Exp Biol Med Date: 2001-04 Impact factor: 0.804
Authors: B M Reipert; S Tanneberger; A Pannetta; M Bedosti; M Poell; K Zimmermann; M T Stellamor Journal: Cancer Immunol Immunother Date: 2005-04-28 Impact factor: 6.968
Authors: Caroline M van Geelen; Jantine L Westra; Elisabeth G de Vries; Wytske Boersma-van Ek; Nynke Zwart; Harry Hollema; H Marike Boezen; Nanno H Mulder; John T Plukker; Steven de Jong; Jan H Kleibeuker; Jan J Koornstra Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: Fabien B Vincent; Rangi Kandane-Rathnayake; Rachel Koelmeyer; James Harris; Alberta Y Hoi; Fabienne Mackay; Eric F Morand Journal: Lupus Sci Med Date: 2020-06